ClinicalTrials.gg
RecruitingNCT05841186Updated Sep 19, 2024

Correlation of Timing of Pegfilgrastim Administration and PIBP.

An interventional study of Timing of pegfilgrastim administration in Pegfilgrastim, Bone Pain and Chemotherapy, sponsored by Guangdong Provincial People's Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Guangdong Provincial People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Breast Neoplasms by Guangdong Provincial People's Hospital — 13 open to participants now, 14 under way, 3 of them phase 3. Breast Neoplasms · Guangdong Provincial People's Hospital.

Planned enrollment
13th of 23
156 · median 160
Started
2023
with 1 other
No phase
8 of 24
6 open now
Primary completion
2025-05
later than 3 of 13 live
Registered
14th of 24
by date

Among the 24 studies in Breast Neoplasms by Guangdong Provincial People's Hospital, this one is the 13th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 14th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 24 studies in Breast Neoplasms by Guangdong Provincial People's Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Breast Neoplasms by Guangdong Provincial People's Hospital, or all of them as a file.
02

Study summary

According to the National Comprehensive Cancer Network (NCCN) guidelines, patients receiving high-risk or moderate-risk febrile neutropenia (FN) chemotherapy with at least one risk factor should receive prophylactic granulocyte colony-stimulating factors (G-CSFs). However, pegfilgrastim-induced bone pain (PIBP) remains a common and significant clinical issue without a satisfactory solution. Studies have reported that the incidence rate of PIBP is 71.3%, with severe bone pain occurring in 27.0% of cases. Currently, the available data on PIBP treatment are limited to case reports, reviews, and small randomized controlled trials.

The NCCN guidelines recommend preventive oral non-steroidal anti-inflammatory drugs or antihistamines as the treatment for PIBP. However, even with these preventive measures, the incidence rate of PIBP remains high at 61.1%, with severe bone pain occurring in 19.2% of cases. Severe bone pain can significantly impact the patient's health-related quality of life (HRQol), leading to potential refusal of pegfilgrastim administration and subsequent dose reduction in effective chemotherapy. Ultimately, this may have negative implications for tumor cure rates and patient survival.

Based on previous literature, it appears that delaying the administration of pegfilgrastim may be associated with a lower incidence of PIBP. Therefore, our study aims to investigate the correlation between the timing of pegfilgrastim administration and the occurrence of PIBP.

03

Conditions studied

  • Pegfilgrastim
  • Bone Pain
  • Chemotherapy
  • Breast Cancer
  • Patient-reported Outcomes
  • Quality of Life

Browse trials for

Keywords

  • pegfilgrastim
  • bone pain
  • patient-reported outcomes
  • chemotherapy
  • Breast Cancer
  • health related-quality of life
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater than or equal to 18 years and less than or equal to 70 years.
  2. or histologically confirmed diagnosis of primary breast cancer.
  3. Able to receive the chemotherapy regimen as scheduled.
  4. Able to understand Chinese and fill out the study-related questionnaires independently.
  5. Given written .
  6. There is no need to use prescription or over-the-counter drugs regularly because of pre-existing chronic pain.

Exclusion criteria

Exclusion Criteria:

  1. Suffering from bone pain due to other diseases currently.
  2. Allergy or to chemotherapeutic agents or pegfilgrastim.
  3. Previous use of pegfilgrastim.
  4. Previous received chemotherapy.
  5. Pregnancy or breastfeeding.
  6. Concurrently accompanied by other primary malignant tumors.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Other
    24h group

    Pegfilgrastim is administrated 24 hours after completing the chemotherapy in the 24-hour group.

    Other: Timing of pegfilgrastim administration

  • Other
    48h group

    Pegfilgrastim is administrated 48hours after completing the chemotherapy in the 48-hour group.

    Other: Timing of pegfilgrastim administration

  • Other
    72h group

    Pegfilgrastim is administrated 72 hours after completing the chemotherapy in the 72-hour group.

    Other: Timing of pegfilgrastim administration

Interventions

  • OtherTiming of pegfilgrastim administration

    Timing of pegfilgrastim administration

06

What researchers measure

Primary outcomes

  1. The area under the curve (AUC) for daily worst bone pain score for days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration) in cycle 1.

    Measured by Brief Pain Inventory-Short Form

    Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).

Secondary outcomes

  1. Incidence of bone pain

    Measured by Brief Pain Inventory-Short Form

    Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).

  2. Incidence of severe bone pain

    Measured by Brief Pain Inventory-Short Form

    Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).

  3. Duration of bone pain and severe bone pain

    Measured by Brief Pain Inventory-Short Form

    Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).

  4. Impact of bone pain on daily life and other aspects.

    Measured by Brief Pain Inventory-Short Form

    Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).

  5. Change From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) Score.

    The EORTC QLQ-C30 is a questionnaire to assess quality of life (QoL), it is composed of 30 questions (items) resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, pain), and 6 single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status indicate a better quality of life; a positive change from baseline indicates improvement. Lower scores on the symptom and single-item scales indicate a better quality of life; a negative change from baseline indicates improvement.

    Time frame: Before pegfilgrastim administration in the first chemotherapy cycle (baseline), day 7 after each cycle of pegfilgrastim administration.

  6. Change From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Breast Cancer-23 (EORTC QLQ-BR23) Score.

    The EORTC QLQ-BR23 is a questionnaire to assess quality of life (QoL), it is composed of 23 questions (items) resulting in 4 functional scales (Body Image, Future Perspective, Sexual Functioning, Sexual Enjoyment) and 4 symptom scales (Systemic Therapy Side Effects, Upset by Hair Loss, Arm Symptoms, Breast Symptoms). All of the scales measures range in score from 0 to 100. Higher score for the functioning scales indicate a better quality of life; a positive change from baseline indicates improvement. Lower scores on the symptom scales indicate a better quality of life; a negative change from baseline indicates improvement.

    Time frame: Before pegfilgrastim administration in the first chemotherapy cycle (baseline), day 7 after each cycle of pegfilgrastim administration.

  7. Change From Baseline in European Quality of Life-Five Dimension-Five Level Scale (EQ-5D-5L) Score.

    The EQ-5D-5L consists of a descriptive system that defines health in terms of five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a visual analog scale (VAS) for respondents to rate their current health status from 0 (worst health) to 100 (best imaginable health). A unique EQ-5D-5L health state (or profile) for each patient was generated by combining the results for the dimensions, consisting of a five-digit code. The health states were then converted to a preference-weighted summary score (weights derived from the general population), or EQ-5D-5L health utility index, with higher scores indicating better outcomes, and a positive change from baseline indicates improvement.

    Time frame: Before pegfilgrastim administration in the first chemotherapy cycle (baseline), day 7 after each cycle of pegfilgrastim administration.

  8. Analgesic use

    According to the diary written by the patient about the use of the analgesic.

    Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).

  9. The area under the curve (AUC) for daily worst bone pain score for days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration) in every cycle.

    Measured by Brief Pain Inventory-Short Form

    Time frame: Days 1 through 5 (day 1 is defined as the day of pegfilgrastim administration).

  10. Leukocyte count

    Measured by blood routine tests.

    Time frame: Patients do blood routine tests on the seventh day of each chemotherapy cycle (Each cycle lasts 28 days, and day 1 denotes the day of chemotherapy completion) and when necessary.

  11. Incidence of febrile neutropenia

    Measured by thermometer and blood routine tests.

    Time frame: Patients monitor their oral temperature daily, and do blood routine tests on the seventh day of each chemotherapy cycle (Each cycle lasts 28 days, and day 1 denotes the day of chemotherapy completion) and when necessary.

  12. Incidence of neutropenia

    Measured by blood routine tests.

    Time frame: Patients do blood routine tests on the seventh day of each chemotherapy cycle (Each cycle lasts 28 days, and day 1 denotes the day of chemotherapy completion) and when necessary.

  13. Absolute neutrophil count

    Measured by blood routine tests.

    Time frame: Patients do blood routine tests on the seventh day of each chemotherapy cycle (Each cycle lasts 28 days, and day 1 denotes the day of chemotherapy completion) and when necessary.

07

Study locations

1 of 1 sites recruiting
  • Department of Breast Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences)
    Guangzhou, Guangdong 510080, China
    Recruiting
    • Kun Wang, professor · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2025, 24 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2023
First posted
May 3, 2023
StartActual
May 4, 2023
Primary completionEst.
May 31, 2025
CompletionEst.
May 31, 2025
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05841186
Responsible party
Kun Wang (professor, Guangdong Provincial People's Hospital) — Principal investigator
First posted
May 3, 2023
Start date
May 4, 2023
Primary completion
May 31, 2025 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Sep 19, 2024

Study contacts

Kun Wang, professor
Contact
gzwangkun@126.com
13922118086
Kun Wang, professor
principal investigator · Guangdong Provincial People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion